Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269541 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GAAHPGDHSD17B10CDK4 | |
| SCHEMBL5963318 | 0.83 | GABRA1 (0.41) | ALDH1A1GAAHPGDHSD17B10GABRA1 | |
| SCHEMBL5962947 | 0.80 | CRBN (0.36) | ALDH1A1GAAHPGDHSD17B10NOS1 | |
| SCHEMBL11458112 | 0.77 | CDK5 (0.38) | ALDH1A1GAAHPGDHSD17B10CDK4 | |
| SCHEMBL2600442 | 0.77 | KMT2A (0.41) | ALDH1A1HSD17B10GABRA1GABRG2GABRB3 | |
| SCHEMBL5962874 | 0.77 | KMT2A (0.41) | ALDH1A1HSD17B10GABRA1GABRG2GABRB3 | |
| SCHEMBL19339957 | 0.77 | HTR2C (0.40) | ALDH1A1HSD17B10GABRA1GABRG2GABRB3 | |
| SCHEMBL17915861 | 0.76 | ERBB2 (0.36) | HSD17B10GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16069934 | 0.75 | GABRP (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19339958 | 0.74 | MEN1 (0.38) | ALDH1A1HSD17B10GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536726-B1 | DIARYL ETHER LINKED PYRROLO [2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2015-03-04 | — | — | EP | claimed |
| EP-2536726-A1 | DIARYL ETHER LINKED PYRROLO [2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2012-12-26 | — | — | EP | claimed |
| WO-2012110840-A1 | DIARYL ETHER LINKED PYRROLO [2,1-C][1,4] BENZODIAZEPINE HYBRIDS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-23 | — | — | WO | claimed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2023227660-A1 | NECTIN-4 BINDING AGENTS | INNATE PHARMA (FR) | 2023-11-30 | — | — | WO | disclosed |
| US-20230201366-A1 | ANTI-PSMA CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2023-06-29 | — | — | US | disclosed |
| US-11377492-B2 | NKp46 binding agents | INNATE PHARMA (FR) | 2022-07-05 | — | — | US | disclosed |
| WO-2022112356-A1 | TREATMENT OF CANCER | INNATE PHARMA (FR) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022097047-A1 | TREATMENT METHODS USING ANTI-BCMA ANTIBODY-DRUG CONJUGATES | MEDIMMUNE, LLC (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20210380605-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-11027021-B2 | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors | SEAGEN INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-1608650-B1 | PYRENE-LINKED PYRROLO(2,1-C)(1,4)BENZODIAZEPINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | COUNCIL SCIENT IND RES (IN) | 2010-06-02 | — | — | EP | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| US-20070191349-A1 | C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases | SPIROGEN LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| EP-1720880-A1 | C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEREOF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Spirogen Limited (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085250-A8 | C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LTD (GB) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005085250-A1 | C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-6800622-B1 | DNA BINDING, ANTITUMOUR ACTIVITY | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-05 | — | — | US | disclosed |
| US-20040192677-A1 | PYRENE-LINKED PYRROLO[2,1--C][1,4]BENZODIAZEPINE HYBRIDS USEFUL AS ANTI-CANCER AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192677-A1 | PYRENE-LINKED PYRROLO[2,1--C][1,4]BENZODIAZEPINE HYBRIDS USEFUL AS ANTI-CANCER AGENTS | TOP2B, TOP1, PBRM1 | ALDH1A1 1156/4885GAA 2928/4885HPGD 2272/4885 |
| US-11377492-B2 | NKp46 binding agents | LY96, CD74, CD2BP2 | ALDH1A1 2300/4885GAA 1250/4885HPGD 3544/4885 |
| US-20070191349-A1 | C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases | TSPO, GABRD, BCOR | ALDH1A1 1722/4885GAA 1738/4885HPGD 115/4885 |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | ALDH1A1 553/4885GAA 233/4885HPGD 3836/4885 |
| US-20230201366-A1 | ANTI-PSMA CONJUGATES | KLK3, FOLH1, CD47 | ALDH1A1 1358/4885GAA 232/4885HPGD 2982/4885 |
| US-11027021-B2 | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors | BCL3, BAK1, MCL1 | ALDH1A1 2142/4885GAA 3086/4885HPGD 2481/4885 |
| US-20210380605-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | PRLHR, GLRA1, CXCR1 | ALDH1A1 1373/4885GAA 2691/4885HPGD 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.